

**FOR IMMEDIATE RELEASE**

## **MedMira Board of Directors Re-elected at Annual Shareholders Meeting**

*Halifax, Nova Scotia, February 5, 2015* – MedMira Inc. (MedMira) (TSXV: MIR) reported that the Company's Board of Directors, comprised of Mr. Hermes Chan, Dr. Colin MacGillivray, Mr. Marvyn Robar, Mr. Romano Robusto, and Dr. Michael Sidler, was re-elected at its 2015 Annual General Meeting of Shareholders. Mr. Robar remains as Chairman of the Board. Shareholders also approved the appointment of Deloitte LLP as the Company's auditors during the meeting held January 30, 2015 in Halifax, N.S.

### **About MedMira**

MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit [medmira.com](http://medmira.com).

*This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **MedMira Contact:**

Andrea Young, Corporate Communications

Tel: 902-450-1588

Email: [ayoung@medmira.com](mailto:ayoung@medmira.com)